Hepatic resection for noncolorectal, nonneuroendocrine metastases: A fifteen-year experience with ninety-six patients

Harrison, Lawrence E.; Brennan, Murray F.; Newman, Elliot; Fortner, Joseph G.; Picardo, Anthony; Blumgart, Leslie H.; Fong, Yuman

doi:10.1016/s0039-6060(97)90050-7

Cited by 179 publications

(115 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, some small patient cohorts were included in retrospective studies that were dedicated to the liver resection of non-colorectal metastases and later, the liver resection of non-colorectal-non-neuroendocrine metastases [15][16][17]. The first publication dedicated to the clinical outcome after liver resection for gastric cancer metastases was presented by Ochiai et al [6]: they described serosal perforation by the primary tumor (in cases of synchronous liver metastases) as well as lymphangiosis and venangiosis to be negative prognostic factors, and reported a median survival time of 18 months and an overall 5-year survival rate of 19%.…”

Section: Discussionmentioning

confidence: 99%

Resection of liver metastases is beneficial in patients with gastric cancer: report on 15 cases and review of literature

et al. 2011

View full text Add to dashboard Cite

Background Although up to 9% of patients with gastric cancer develop liver metastases, liver resection is rarely performed because of co-existing non-curative factors. Furthermore, the benefit of liver resection is still controversially discussed. Our goal was to investigate the outcome of patients who underwent liver resection or radiofrequency ablation (RFA) for hepatic metastasized gastric cancer. Methods Retrospectively collected data from a prospectively maintained database were analyzed from 15 patients who underwent liver resection or RFA for liver metastases from gastric cancer. Results Overall 5-year survival and median survival were 27% and 48 months for resected/RFA patients. The perioperative complication rate was low. One patient has been tumor-free for 90 months now. Conclusions Liver resection in patients with hepatic metastasized gastric cancer is beneficial and safe if an R0 situation can be achieved. RFA might be a useful alternative in those patients where surgery is not feasible.

show abstract

Section: Discussionmentioning

confidence: 99%

Resection of liver metastases is beneficial in patients with gastric cancer: report on 15 cases and review of literature

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Dentre os mais importantes a nosso ver e que foram seguidos a risca foram: intervalo livre de doença e número de lesões. Somente foram operados doentes com lesões metacrônicas (intervalo livre de doença maior que seis meses) e de preferên-cia doentes com lesão única e no máximo quatro, isto baseado em diversos estudos que demonstraram baixa sobrevida para indivíduos com metástases sincrônicas ( 2,6,8,10,11,13,14,24,29). Fato que foi confirmado nesse estudo, onde o número de lesões (maior que uma) foi uma variável independente no prognóstico.…”

Section: Tabela 5 -Características Dos Sobreviventes Livres De Doençaunclassified

“…E seus resultados em longo prazo têm sido surpreendentes quando realizadas em casos adequadamente selecionados. Metástases de tumores do trato genito-urinário, de mama e de sarcomas parecem apresentar resultados comparáveis aos de origem CR (9)(10)(11)(12)(13)(14)(15)(16)(17)(18). Em nossas meio, pequenas séries de casos de ressecção hepática de metástases de sarcomas, mama e também de outros primários tem sido também descritas (19)(20)(21).…”

unclassified

Hepatectomia para o tratamento de metástases colorretais e não-colorretais: análise comparativa em 30 casos operados

Costa

Horta

Henriques

et al. 2009

Rev bras. colo-proctol.

View full text Add to dashboard Cite

INTRODUÇÃOAtualmente, a ressecção cirúrgica de metástases hepáticas de etiologia colorretal é a única modalidade com intenção curativa ou de prolongamento da sobrevida. Em séries mais recentemente publicadas, a sobrevida dos pacientes submetidos à sua ressecção completa (R0) tem variado de 25 % até 55 % em cinco anos (1-3). Em contrapartida, quando indivíduos com disseminação hepática são submetidos a tratamento quimioterápico exclusivo, raramente alcançam mais do que três anos de sobrevida (4).

show abstract

“…Several small retrospective series have reported 5-year survival rates of 0% to 37%. 79,[83][84][85] Harrison et al 83 reported the best outcome in patients with genitourinary and gynecologic primary tumors, compared with those with soft tissue metastases and nonsarcomatous gastrointestinal primary tumors. Others suggest that gynecologic malignancies are not candidates for liver resection because of the poor long-term survival.…”

Section: Results Of Liver Resection For Colorectal Metastasesmentioning

confidence: 99%

Management of hepatic metastases

Choti

Bulkley

1999

Liver Transpl

View full text Add to dashboard Cite

Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both intrahepatically and extrahepatically, is important before considering treatment options. Based on a preponderance of uncontrolled studies for hepatic metastatic colorectal carcinoma, surgical resection offers the only potential for cure of selected patients with completely resected disease, with 5-year survival rates of 25% to 46%. Systemic and hepatic arterial infusion chemotherapy may be useful treatment options in patients with unresectable disease and possibly as an adjuvant treatment after liver resection. Other techniques of local tumor ablation, including cryotherapy and radiofrequency ablation, although promising, remain unproved. Management of hepatic metastases from neuroendocrine tumors and other noncolorectal primary tumors should be individualized based on the patient's clinical course, extent of disease, and symptoms. Copyright 1999 by the American Association for the Study of Liver DiseasesA s many as 50% of the patients with a primary malignancy will eventually develop metastases in the liver, a percentage greater than for any other organ, including the lung. Although primary tumors that drain principally into the portal circulation are more likely than others to develop hepatic metastases, many tumors arising in other sites, such as the breast and lung, also commonly develop hepatic metastases. Although the liver represents a common site of spread from many of these solid tumors, isolated hepatic metastases most commonly occur from colorectal and neuroendocrine tumors. Other less common malignancies also can metastasize predominantly to the liver. For most other solid malignancies, the pattern of metastatic disease is most often that of generalized dissemination. Colorectal MetastasesCancer of the colon and rectum is the third most commonly diagnosed cancer in the United States. An estimated 131,600 new cases will have been discovered in 1998, comprising 11% of new cancer diagnoses. 1 An estimated 56,500 deaths will occur from colorectal cancer that year, comprising 10% of all cancer deaths. 1 Although mortality from largebowel cancer has been improving over the past 30 years, largely because of improvements in early detection, diagnosis, and treatment, approximately 50% of the patients with colorectal cancer eventually die of their neoplastic disease. 1 The liver is the most commonly involved organ in patients with metastatic colorectal cancer. Approximately 20% of these patients have clinically recognizable liver metastases at the time of their primary diagnosis. 1,2 After resection of a primary colorectal cancer in the absence of apparent metastatic disease, approximately 50% of the patients will subsequently manifest metastatic liver disease. Given these figures,...

show abstract

Hepatic resection for noncolorectal, nonneuroendocrine metastases: A fifteen-year experience with ninety-six patients

Cited by 179 publications

References 17 publications

Resection of liver metastases is beneficial in patients with gastric cancer: report on 15 cases and review of literature

Resection of liver metastases is beneficial in patients with gastric cancer: report on 15 cases and review of literature

Hepatectomia para o tratamento de metástases colorretais e não-colorretais: análise comparativa em 30 casos operados

Management of hepatic metastases

Contact Info

Product

Resources

About